Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics (Nasdaq: TARA) announced the grant of inducement non-qualified stock options for 3,700 shares to a new employee. The exercise price is set at $51.12, equivalent to Protara's closing price on June 1, 2020. The options will vest over four years, with 25% cliff vesting on the first anniversary, followed by monthly vesting. The award aligns with NASDAQ Listing Rule 5635(c)(4) and is designed to attract talent for Protara's focus on rare diseases, including TARA-002 for lymphatic malformations and IV choline chloride for intestinal failure-associated liver disease.
Protara Therapeutics, previously ArTara Therapeutics, has announced its name change effective immediately, with shares continuing to trade under the ticker symbol TARA. The rebranding aims to enhance the company's identity and commitment to developing innovative therapies for rare diseases. Its lead drug candidate, TARA-002, targets lymphatic malformations and is based on OK-432, a treatment approved in Japan and Taiwan. Protara also has IV Choline Chloride as a Phase 3-ready therapy for patients with intestinal failure associated liver disease. A new corporate website has been launched.
ArTara Therapeutics (TARA) announced the grant of inducement stock options totaling 4,100 shares to two new employees at an exercise price of $24.02 per share, equivalent to the May 1, 2020 closing price. These options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. The Compensation Committee approved these awards in line with NASDAQ Listing Rule 5635(c)(4). ArTara focuses on developing treatments for rare diseases, including TARA-002 for lymphatic malformations and IV choline chloride for intestinal failure-associated liver disease.